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introduction
The overall prognosis of patients with non-molecularly selected advanced nonsmall-cell lung cancer (NSCLC) is poor. In East Asia, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) gefitinib is widely used [1] . In clinical trials, dramatic responses have been observed soon after initiation of treatment, particularly in Asians, women, nonsmokers, and adenocarcinoma cases [2] . For patients with tumors harboring activating EGFR mutations, gefitinib could significantly prolong progression-free survival (PFS) compared with cytotoxic chemotherapy [3] . However, drug resistance eventually develops in most patients despite the initial good response, with a median PFS of ∼1 year [4] .
Resistance to EGFR-TKI has been associated with the acquisition of EGFR T790M mutation) [5] and overexpression and/or activation of c-Met [6, 7] . There are also other potential genetic factors associated with EGFR gene mutations that may be useful to predict the likelihood of response or resistance to EGFR-TKI.
In contrast with EGFR signaling pathway, the transforming growth factor-β (TGF-β) signaling pathway is strongly antiproliferative, which plays an important role in tumorigenesis, cancer progression and metastasis via crosstalk with Smad and EGFR signaling pathways, like P13K/AKT and receptor prodn-tyrosine phosphatase-к [8, 9] . To our knowledge, TGF-β signaling pathway has two major mechanisms to affect the outcome of EGFR-TKI. First, epithelial-mesenchymal transition (EMT) is one of the important mechanisms of TKI resistant, and changes in EMT status can explain resistance to EGFR-TKI [10, 11] . Receptor Smads (Smad2 and particularly Smad3), the direct targets of the activated TGF-β receptor, have been implicated as critical mediators in EMT [11] . Secondly, Bcl-2L11 (BIM) associated with TKI resistance [12] , and one target of Smad3 in inducing apoptosis is Bcl-2, a key antiapoptotic inhibitor. TGF-β/Smad3 signaling facilitates a permissive cellular context that is tending to promote apoptosis by attenuating the level of the major apoptosis inhibitor Bcl-2 [13] .
The purpose of our study is to determine whether genetic variations in the TGF-β signaling pathway are associated with survival in NSCLC patients treated with EGFR-TKI, especially in the patients with EGFR mutation. (Figure 1 ). Eligible and exclusion criteria described in supplementary File S1, available at Annals of Oncology online. The EGFR mutations were detected by DNA sequencing (supplementary File S1, available at Annals of Oncology online), Amplification-refractory mutation system or mutant-enriched liquidchip ( 
materials and methods

treatment and follow-up
Among 206 patients, 143 patients were treated with oral gefitinib between January 2009 and December 2011. Survival information was collected every 2 months from the specific doctor's follow-up records; and all the patients were asked to return to the hospital for examination [15] . Free gefitinib program (Iressa Means-Tested Drug Donation) is supported by China Charity Federation (www.Iressaccf.org). The patients needed pay for the treatment in the first 6 months, than they received the free drugs until disease progression or death. PFS was defined as the time from first dose of gefitinib to the date of obvious disease progression or death due to any causes. Overall survival (OS) was defined as the time between first dose of gefitinib and death or the last follow-up. Dates of death were obtained from (i) inpatient and outpatient records, (ii) patient's family reports. Living patients were censored at the last date they were known to be alive based on the date of the last contact.
polymorphism selection and genotyping
In this study, a total of 33 single-nucleotide polymorphism (SNPs) in 13 candidate genes of the TGF-β signaling pathway were selected based on the following criteria (supplementary Table S1 , available at Annals of Oncology online). All the SNPs were either located in the promoter untranslated region or coding region of the gene or those that had been previously reported as being associated with survival, lung cancer, or metastasis ( Table 3 ). All of them were selected using HaploView software with HapMap HCB data in a pairwise mode and all correlated alleles were captured at r 2 > 0.8 [16] . In this study, the genes (number of SNPs) were including TGF-β1(3), TGFβR1(3), BMP1(2), BMP2(1), BMP4(2), SMAD1(1), SMAD3(7), SMAD4(6), SMAD6(3), SMAD7
(1), SMAD8(2), VEGF(4), CDH(1), INHBC(1), and ACVR2A(1) [16, 17] (for details, see supplementary Table S1 , available at Annals of Oncology online).
dual luciferase reporter assay and western blot
We used dual luciferase reporter assay and western blot to analyze the function of SMAD3 rs11632964, which was significantly associated with survival time of Table. EGFR, epidermal growth factor receptor; SD, standard deviation; TNM, tumor-node-metastasis; ECOG, Eastern Cooperative Oncology Group. 
individual SNPs and survival
The association of all SNPs with OS and PFS is summarized in supplementary Tables S1-S4, available at Annals of Oncology online. We identified two SNPs with P < 0.05 and one SNP with P < 0.01, and all of them belonged to SMAD3 ( Table 2) . The most significant association in this study was found to be with SMAD3: rs11632964. Among the whole group of patients, wild-type SMAD3: rs11632964 was associated with an increased risk of death and disease progression. The patients with SMAD3: rs11632964 had a decreased median survival time (MST) of 15.9 months compared with 30.8 months for those with variant allele (log-rank P = 0.037, Figure 2A ). Similar result was also found in PFS. Patients carrying variant allele had a longer PFS (13.2 versus 9.2 months) compared with those with the wild type ( Figure 2B ). In the patients with EGFR mutations, the efficacy of SMAD3: rs11632964 was found to be more obvious. The differences of OS and PFS in the patients with wild type versus variant genotypes of SMAD3: rs11632964 were more significant. Patients with variant allele also had much longer MST (30.8 versus 17.5 months; log-rank P = 0.020) and PFS (20.8 months versus 9.4 months; log-rank P = 0.001) than those with wild type (Figure 2C and D) . SMAD3: rs11071938 variant genotype was also significantly associated with better PFS (95% CI 1.01-2.31, P = 0.045) in the whole cohort (11.8 versus 9.2 months); and the patients with the EGFR mutations, SMAD3: rs11071938 variant genotype was associated better PFS (14.2 versus 9.9 months; HR = 1.75, 95% CI 1.06-2.89, P = 0.029) ( Figure 2E) .
Different from the two SNPs described above, it was the wildtype genotype of SMAD3: rs6494633 that was associated with improved PFS in EGFR-mutated patients. These individuals had more than 2 months disease control advantage with PFS than those with variant genotype (11.3 versus 8.6 months, log-rank P = 0.048) ( Figure 2F ). The remaining 30 selected SNPs showed no associations between their genotype and the survival time (Table 3; supplementary Tables S2-S5 , available at Annals of Oncology online).
functional evaluation of the SMAD3 rs11632964 polymorphism SMAD3 protein and pi-SMAD3 expression in PC-9 cells and PC9/ G cells were detected first. We found that there was significantly decreased smad3 as well as pi-smad3 in the gefitinib-resistant PC-9/G cells compared with wild-type PC-9 ( Figure 3A and B) . We then examined the regulator role of SMAD3 rs11632964 SNP in these two cell lines. Relative luciferase expression assays indicated that the 651-bp intron 1 region which we cloned in either pGL3b-rs11632964 T construct or pGL3b-rs11632964C construct showed promoter activity. This demonstrates that there might be an intronic promoter region around rs11632964 polymorphism. We next examined whether the survival-related SNP rs11632964 has an allele-specific effect on the intronic promoter activity. PC9/G cells transfected with SMAD3 rs11632964T allelic reporter construct showed significantly lower luciferase activities compared with cells expression C allelic reporter construct (both P < 0.05). However, no such difference was observed in PC9 cells ( Figure 3C ). discussion Currently, the detection of EGFR-TKI-sensitive mutations are essential for selecting the treatments for the patients with advanced NSCLC since these mutations have been shown to be predictive of drug sensitivity. In addition to the well-known EGFR mutations, our previous studies suggested that the polymorphisms of EGFR signaling pathway might be prognostic markers of OS in advanced lung adenocarcinoma patients who were treated with gefitinib [20] . But, we did not find any significant correlation between EGFR SNPs and clinical outcome in the patients carrying EGFR mutations. In the current study, we systematically evaluated genetic variations in 33 SNPs from13 candidate genes and treatment outcome in the patients with advanced lung adenocarcinomas. Among the SNPs we have analyzed, the genetic variations in TGF-β pathway were found to be highly associated with outcome, especially in those with EGFR mutations. To our knowledge, our study is the first to link TGF-β signaling pathway SNPs with lung cancer outcome for in patients with EGFR mutant adenocarcinomas.
The variations of genes in TGF-β pathway are detected in several human cancers. TGF-β signaling pathway possesses a tumor suppressor function [21] . TGF-β and its signaling effectors act as the key determinants of carcinoma cell behavior [22] . There is evidence to suggest that Smad3 plays a major role in TGF-β-mediated growth inhibition. First, Smad3 works in TGF-β-induced antiproliferative transcriptional responses. Secondly, Smad3 works in TGF-β-mediated proapoptotic transcriptional responses [13] . On the other side, TGF-β promotes tumor progression during the late stages of cancer by suppressing immune surveillance, inducing EMT, and enhancing cell migration and transcription of factors favorable to metastasis. Smad3 is directly involved in EMT [23] . Changes of EMT status may underlie acquired resistance of gefitinib [24] . Sordella et al. found erlotinib-resistant cells H1650-M3 were characterized by an upregulation of TGF-β-mediated signaling and increased levels of Smad3 phosphorylation in H1650-M3 cells compared with H1650 cells. Therefore, Smad3 functions as both a negative and positive regulator of carcinogenesis and cancer progression depending on cell type and clinical stage of the tumor [25] .
In the main analysis, SMAD3: rs11632964, showed strong association with treatment outcome. It is possible that the variant allele of SMAD3: rs11632964 affects gene transcription thus altering protein level [16] . Our functional test in lung cancer cell lines suggested that gefitinib-resistant PC9/G cells transfected with SMAD3 rs11632964T allelic reporter construct showed significantly lower luciferase activities compared with cells expression C allelic reporter construct, and no such difference was observed in PC9 cells [26] . We also found that there was significantly decreased smad3 as well as pi-smad3 in PC-9/G cells compared with wild-type PC-9. The results of two functional tests were consistent and demonstrated that individuals with decreased expression of SMAD3 caused by the rs11632964 T allele might contribute to shortened survival time after gefitinib treatment. Our study has a complete clinical dataset with EGFR mutation status determined in all the patients. Although function is not known for all gene variations, this study suggests biological implications of these genetic variations in treatment selection and outcome. This study will help us choose the patients who can get more clinical benefit from TKI therapy except EGFR mutation. It has been reported that a haplotype of SMAD3 is associated with OS of NSCLC patients, which is the support of our results [16] . In conclusion, our data show that genetic variations in TGF-β pathway are the potential predictors of outcome in advanced lung adenocarcinoma with EGFR mutations. Analysis of these genetic variations, in addition to EGFR mutation detection, may refine the drug selection process for the treatment of advanced lung adenocarcinomas and improve the prediction of the treatment outcome. However, as a single institutional study, our patient number was relatively small. We need a larger patient population and better mapping and functional assays to validate the results. 
